SPOCD1 promotes cell proliferation and inhibits cell apoptosis in human osteosarcoma

Liang,Jinqian; Zhao,Hong; Hu,Jianhua; Liu,Yong; Li,Zheng

doi:10.3892/mmr.2017.8263

SPOCD1 promotes cell proliferation and inhibits cell apoptosis in human osteosarcoma

Authors:
- Jinqian Liang
- Hong Zhao
- Jianhua Hu
- Yong Liu
- Zheng Li
View Affiliations

Affiliations: Department of Orthorpaedic Surgery, Peking Union Medical College Hospital, Beijing 100730, P.R. China
Published online on: December 12, 2017 https://doi.org/10.3892/mmr.2017.8263
Pages: 3218-3225

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common type of malignant bone tumors that typically affects adolescents and children. The spen paralogue and orthologue C‑terminal domain containing 1 (SPOCD1) is a newly identified molecule that has been indicated to discriminate progressive from non‑progressive bladder cancers. However, the role of SPOCD1 in human solid tumors remains largely unknown. In the present study, SPOCD1 was upregulated in clinical osteosarcoma tissues compared with adjacent non‑cancerous tissues. Furthermore, SPOCD1 was upregulated in osteosarcoma cell lines and expression was particularly increased in highly invasive cells MG63 and SAOS2. Further investigation revealed that downregulation of SPOCD1 inhibited the MG63 and SAOS2 osteosarcoma cell colony formation and proliferation capacity. In addition, cell apoptosis was promoted by knockdown of SPOCD1 in MG63 and SAOS2 cells. These effects were confirmed by measuring the Ki67 and PCNA expression. In addition, SPOCD1 positively regulated the expression of vascular endothelial growth factor A (VEGF‑A). Knockdown of VEGF‑A blunted SPOCD1 downregulation‑mediated inhibition of cell proliferation and induction of cell apoptosis. These results suggested that SPOCD1 may act as a pro‑oncogenic factor in osteosarcoma. Inhibition of VEGF may aid in treating osteosarcoma in clinic.

View Figures

View References

1	van der Deen M, Taipaleenmäki H, Zhang Y, Teplyuk NM, Gupta A, Cinghu S, Shogren K, Maran A, Yaszemski MJ, Ling L, et al: MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem. 288:21307–21319. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wang P, Wang H, Li X, Liu Y, Zhao C and Zhu D: SRCIN1 suppressed osteosarcoma cell proliferation and invasion. PLoS One. 11:e1555182016.
3	Cao Y, Wu T, Li D, Hu J and Lu H: MicroRNA-336 directly targets Sox-2 in osteosarcoma to inhibit tumorigenesis. Mol Med Rep. 15:4217–4224. 2017. View Article : Google Scholar : PubMed/NCBI
4	Zhang C, Yao C, Li H, Wang G and He X: Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas. Int J Mol Sci. 15:6544–6555. 2014. View Article : Google Scholar : PubMed/NCBI
5	Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, et al: Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells. 32:959–973. 2014. View Article : Google Scholar : PubMed/NCBI
6	Iwasaki T, Tanaka K, Kawano M, Itonaga I and Tsumura H: Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells. Int J Oncol. 46:1543–1550. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K, Wakaguri H, et al: Diversification of transcriptional modulation: Large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 16:55–65. 2006. View Article : Google Scholar : PubMed/NCBI
8	Fardilha M, Esteves SL, Korrodi-Gregório L, Vintém AP, Domingues SC, Rebelo S, Morrice N, Cohen PT, da Cruz e Silva OA and da Cruz e Silva EF: Identification of the human testis protein phosphatase 1 interactome. Biochem Pharmacol. 82:1403–1415. 2011. View Article : Google Scholar : PubMed/NCBI
9	van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A and Witjes JA: A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 64:127–136. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zhu M, Yan C, Ren C, Huang X, Zhu X, Gu H, Wang M, Wang S, Gao Y, Ji Y, et al: Exome array analysis identifies variants in SPOCD1 and BTN3A2 that affect risk for gastric cancer. Gastroenterology. 152:2011–2021. 2017. View Article : Google Scholar : PubMed/NCBI
11	Wang Y and Tatakis DN: Human gingiva transcriptome during wound healing. J Clin Periodontol. 44:394–402. 2017. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Davis AM, Bell RS and Goodwin PJ: Prognostic factors in osteosarcoma: A critical review. J Clin Oncol. 12:423–431. 1994. View Article : Google Scholar : PubMed/NCBI
14	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
15	Trieb K and Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol. 33:11–17. 2001. View Article : Google Scholar : PubMed/NCBI
16	Luscan A, Shackleford G, Masliah-Planchon J, Laurendeau I, Ortonne N, Varin J, Lallemand F, Leroy K, Dumaine V, Hivelin M, et al: The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis. Clin Cancer Res. 20:358–371. 2014. View Article : Google Scholar : PubMed/NCBI
17	Liu H, Zhou Y and Tang L: Caffeine induces sustained apoptosis of human gastric cancer cells by activating the caspase-9/caspase-3 signalling pathway. Mol Med Rep. 16:2445–2454. 2017.PubMed/NCBI
18	Liu JY, Liu Z, Wang DM, Li MM, Wang SX, Wang R, Chen JP, Wang YF and Yang DP: Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chem Biol Interact. 190:91–101. 2011. View Article : Google Scholar : PubMed/NCBI
19	Saharinen P, Eklund L, Pulkki K, Bono P and Alitalo K: VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 17:347–362. 2011. View Article : Google Scholar : PubMed/NCBI
20	Germani A, Di Carlo A, Mangoni A, Straino S, Giacinti C, Turrini P, Biglioli P and Capogrossi MC: Vascular endothelial growth factor modulates skeletal myoblast function. Am J Pathol. 163:1417–1428. 2003. View Article : Google Scholar : PubMed/NCBI
21	Sullivan LA and Brekken RA: The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs. 2:165–175. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
23	Roberts SS, Chou AJ and Cheung NK: Immunotherapy of childhood sarcomas. Front Oncol. 5:1812015. View Article : Google Scholar : PubMed/NCBI
24	Armakolas N, Armakolas A, Antonopoulos A, Dimakakos A, Stathaki M and Koutsilieris M: The role of the IGF-1 Ec in myoskeletal system and osteosarcoma pathophysiology. Crit Rev Oncol Hematol. 108:137–145. 2016. View Article : Google Scholar : PubMed/NCBI
25	Chen Q, Zhou Z, Shan L, Zeng H, Hua Y and Cai Z: The importance of Src signaling in sarcoma. Oncol Lett. 10:17–22. 2015.PubMed/NCBI
26	Hermo GA, Torres P, Ripoll GV, Scursoni AM, Gomez DE, Alonso DF and Gobello C: Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. Vet J. 178:103–108. 2008. View Article : Google Scholar : PubMed/NCBI